trending Market Intelligence /marketintelligence/en/news-insights/trending/Vp8YCD-OBauKzIQ-_EtYCQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA approves Endo's application for low blood pressure injection

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


US FDA approves Endo's application for low blood pressure injection

Endo International PLC's operating company Par Pharmaceutical received final approval from the U.S. FDA for its new drug application for ephedrine sulfate injection.

The drug is a parenterally administered pressor agent to address hypotension, which is low blood pressure, in surgical settings.

U.S. sales of ephedrine sulfate injection products were about $177 million for the 12 months ended Nov. 30, 2016, according to IMS Health data.

Par Pharmaceutical anticipates shipping of the product to begin in February.